Overview and Scope
Multiplex biomarker imaging is a technique that allows for the simultaneous detection and analysis of multiple biomarkers within a single sample, enabling the visualization of complex biological processes and molecular profiles. This method uses advanced imaging technologies to map the spatial distribution of biomarkers within tissues, providing detailed insights into cellular interactions and microenvironments.
Sizing and Forecast
The multiplex biomarker imaging market size has grown rapidly in recent years. It will grow from $0.44 billion in 2023 to $0.49 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to the high incidence of cancer, the need for precise diagnostic tools, the growing prevalence of chronic diseases, the increase in the aging population, and the shift towards personalized medicine.
The multiplex biomarker imaging market size is expected to see rapid growth in the next few years. It will grow to $0.74 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to increasing emphasis on personalized medicine, increased research and development activities, increasing clinical trials, the need for high throughput screening methods in drug discovery, and supportive regulatory frameworks and guidelines. Major trends in the forecast period include technological advancements, innovations in imaging technologies, advances in digital pathology, developments in data analysis and imaging software, and integration of AI and machine learning with imaging technologies.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/multiplex-biomarker-imaging-global-market-report
Segmentation & Regional Insights
The multiplex biomarker imaging market covered in this report is segmented –
1) By Component Type: Instruments, Software, Services
2) By Imaging Techniques: Immuno Fluorescence (IF) Assay, Tissue Microarray (TMA) Assay, Immunohistochemistry (IHC) Assay, Fluorescent In The Situ Hybridization (FISH) Assay, Toponome Imaging System (TIS)
3) By Application: Drug Safety, Oncology Studies, Genetic Characterization Studies
4) By End User: Research Institutes Government And Private, Clinical Labs, Pharmaceutical And Biotechnology
North America was the largest region in the multiplex biomarker imaging market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiplex biomarker imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16127&type=smp
Major Driver Impacting Market Growth
The rising prevalence of chronic diseases is expected to propel the growth of the multiplex biomarker imaging market going forward. Chronic diseases are long-lasting health conditions that persist or recur over time, often with complex causes, multiple risk factors, and long latency periods. The growing prevalence of chronic diseases is attributed to several factors, including the rapid aging of the population, improved case finding and detection, better treatment and management of diseases, and changes in lifestyle and environmental risk factors. Multiplex biomarker imaging is utilized in chronic disease management for comprehensive analysis and characterization of disease progression and treatment response. For instance, in January 2023, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.52 million in 2020 to 142.66 million in 2050. Therefore, the rising prevalence of chronic diseases is driving the growth of the multiplex biomarker imaging market.
Key Industry Players
Major companies operating in the multiplex biomarker imaging market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher corporation, Becton Dickinson and Company (BD), Carl Zeiss AG, Illumina Inc, PerkinElmer Inc., Bio-Rad Laboratories Inc, Bruker Corporation, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Abcam Plc, Meso Scale Diagnostics LLC, Fluidigm Corporation, NanoString Technologies, Quanterix Corporation, Akoya Biosciences, Enzo Biochem Inc, Cisbio Bioassays, Flagship Biosciences, Aushon BioSystems Ltd, Ionpath Inc., Biosims Technologies
The multiplex biomarker imaging market report table of contents includes:
1. Executive Summary
2. Multiplex Biomarker Imaging Market Characteristics
3. Multiplex Biomarker Imaging Market Trends And Strategies
4. Multiplex Biomarker Imaging Market – Macro Economic Scenario
5. Global Multiplex Biomarker Imaging Market Size and Growth
.
.
.
32. Global Multiplex Biomarker Imaging Market Competitive Benchmarking
33. Global Multiplex Biomarker Imaging Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Multiplex Biomarker Imaging Market
35. Multiplex Biomarker Imaging Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
